AlphaYouBV
Schedule 13G filing
BIOTECHNOLOGY VALUE FUND L P disclosed a 5.6% stake in Stoke Therapeutics, Inc. (STOK)
BIOTECHNOLOGY VALUE FUND L P reported owning 5.6% of Stoke Therapeutics, Inc. (STOK) (3,608,968 shares) in a Schedule 13G filed Sep 30, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Sep 30, 2026
- Source
- Schedule 13G
More STOK insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.